4,088 AstraZeneca Plc $AZN Shares Purchased by Phoenix Financial Ltd.

Phoenix Financial Ltd. increased its holdings in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 21.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 23,453 shares of the company’s stock after purchasing an additional 4,088 shares during the period. Phoenix Financial Ltd.’s holdings in AstraZeneca were worth $3,787,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Amundi boosted its position in AstraZeneca by 146,574.4% in the 1st quarter. Amundi now owns 15,386,149 shares of the company’s stock valued at $3,034,456,000 after buying an additional 15,375,659 shares during the period. Janus Henderson Group PLC grew its stake in shares of AstraZeneca by 889.9% in the first quarter. Janus Henderson Group PLC now owns 11,949,424 shares of the company’s stock worth $2,319,947,000 after acquiring an additional 10,742,268 shares in the last quarter. Rathbones Group PLC increased its position in shares of AstraZeneca by 106,772.0% during the first quarter. Rathbones Group PLC now owns 8,054,943 shares of the company’s stock worth $1,560,419,000 after acquiring an additional 8,047,406 shares during the period. Royal Bank of Canada increased its position in shares of AstraZeneca by 208.6% during the first quarter. Royal Bank of Canada now owns 10,386,455 shares of the company’s stock worth $2,048,417,000 after acquiring an additional 7,021,126 shares during the period. Finally, Swiss National Bank purchased a new stake in shares of AstraZeneca during the first quarter worth $1,202,714,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Weiss Ratings upgraded AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 26th. Deutsche Bank raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. Citigroup restated a “buy” rating on shares of AstraZeneca in a report on Tuesday, October 6th. Royal Bank Of Canada assumed coverage on AstraZeneca in a research report on Tuesday, September 8th. They issued an “outperform” rating on the stock. Finally, Wall Street Zen raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Sixteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus price target of $206.67.

Get Our Latest Report on AstraZeneca

AstraZeneca Trading Up 0.1%

NYSE AZN opened at $184.66 on Monday. The company has a quick ratio of 0.79, a current ratio of 1.01 and a debt-to-equity ratio of 0.51. AstraZeneca Plc has a 52 week low of $153.41 and a 52 week high of $212.71. The stock has a market capitalization of $286.40 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 1.43 and a beta of 0.24. The firm has a 50 day moving average of $168.82 and a two-hundred day moving average of $180.20.

AstraZeneca (NYSE:AZN – Get Free Report) last announced its quarterly earnings data on Friday, October 30th. The company reported $2.79 EPS for the quarter, beating analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The company had revenue of $16.21 billion for the quarter, compared to the consensus estimate of $16 billion. During the same period in the prior year, the firm posted $2.38 EPS. The company’s quarterly revenue was up 6.5% compared to the same quarter last year. As a group, research analysts expect that AstraZeneca Plc will post 10.22 EPS for the current fiscal year.

About AstraZeneca

(Free Report)

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

Recommended Stories

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.